Bumetanide is a loop diuretic that is proposed to possess a beneficial effect on disorders of the central nervous system, including neonatal seizures. Therefore, prediction of unbound bumetanide concentrations in the brain is relevant from a pharmacological prospective. A physiologically-based 
integrating physicochemical data and in vitro data. Bumetanide concentration profiles were simulated in both plasma and brain using the Simcyp PBPK model. Simulations of plasma bumetanide concentrations were compared against plasma levels published in the literature. The model performance was verified with data from adult studies before predictions in the paediatric population were undertaken. The adult and paediatric intravenous models predicted pharmacokinetic factors, namely area under the concentration-time curve, maximum concentration in plasma and time to maximum plasma concentration, within two-fold of observed values. However, predictions of plasma concentrations within the neonatal intravenous model did not produce a good fit with the observed values. The PBPK approach used in this study produced reasonable predictions of plasma concentrations of bumetanide, except in the critically ill neonatal population. This PBPK model requires more information regarding metabolic intrinsic clearance and transport parameters prior to further validation of drug disposition predictions in the neonatal population. Given the lack of information surrounding certain parameters in this special population, the model is not appropriately robust to support the recommendation of a suitable dose of bumetanide for use as an adjunct antiepileptic in neonates. Bumetanide is an inhibitor of Na-K-2Cl cation chloride cotransporter (NKCC1) that was initially developed as a loop diuretic for the treatment of oedema in adults and children (Cook et al., 1988; Holazo, Colburn, Gustafson, Young, & Parsonnet, 1984; Lau, Hyneck, Berardi, Swartz, & Smith, 1986; Marcantonio et al., 1982; Marshall, Wells, Letzig, & Kearns, 1998; Oberbauer, Krivanek, & Turnheim, 1995) . It had been suggested that bumetanide may be used as an adjunct antiepileptic with phenobarbital in the treatment of neonatal seizures and a dose-finding clinical trial of bumetanide has been undertaken in a critically ill neonatal cohort (Dzhala, Brumback, & Staley, 2008; Pressler et al., 2015) . The mechanism underlying bumetanide's adjunct antiepileptic activity has been elucidated to be due to the inhibition of intracellular chloride accumulation through NKCC1, thereby facilitating the excitatory to inhibitory switch in gamma-aminobutyric acid signalling (Ben-Ari, 2002) . However, the permeability of bumetanide ClinicalTrials.gov trial registry, NCT01434225 across the blood-brain barrier (BBB) has been predicted and been shown experimentally to be a limiting factor, as it is a highly plasma protein bound, diprotic acid with pKa values of 3.6 and 7.7 (Fiori et al., 2003) , therefore is > 99% ionized at physiological pH. Bumetanide has been shown to be a substrate of human organic anion transporter 3 (OAT3), murine organic anion-transporting polypeptide 1a4 (Oatp1a4) and human multidrug resistance protein 4 (MRP4), which all operate as efflux transporters at the BBB at physiological pH (Donovan, O'Brien, Boylan, Cryan, & Griffin, 2015; Donovan, Schellekens, Boylan, Cryan, & Griffin, 2016; Puskarjov, Kahle, Ruusuvuori, & Kaila, 2014; Römermann et al., 2017) . Despite knowing that the half-maximal inhibitory concentration of bumetanide for NKCC1 is between 200 and 300 nM, it is unknown if, and at what systemic dose, this unbound concentration of bumetanide in the brain can be achieved (Puskarjov et al., 2014) .
Bumetanide is not licensed for use in the paediatric population as 'no clinical trials have been carried out in children' , but its use has been reported in critically ill oedematous children (Health Products Regulatory Authority, 2016; Marshall et al., 1998; Sullivan, Witte, Yamashita, Myers, & Blumer, 1996) . Bumetanide pharmacokinetics in healthy adult volunteers have been described; absorption following oral administration occurs rapidly, with a reported bioavailability of 95% and the maximum plasma concentration observed by 2 h post dosing (Ward & Heel, 1984) . Bumetanide is highly plasma-protein bound (up to 95%), but the range of volumes of distribution is nonetheless large (12-35 litres). The elimination half-life of bumetanide is approximately 1.25 hours. Half of the administered dose is eliminated unchanged in urine, with hepatic metabolism and biliary excretion accounting for the remainder of the excretion (Halladay, Carter, Glenn Sipes, Brodie, & Bressler, 1975; Ward & Heel, 1984) . The main Phase I metabolic route for bumetanide is oxidation of the N-butyl side chain forming inactive alcohol metabolites.
Glucuronidation by UDP-glucuronosyl transferase occurs prior to excretion in the urine and bile (Zisaki, Miskovic, & Hatzimanikatis, 2015) . It has been estimated that up to 20% of the dose is excreted via the faeces (Halladay et al., 1975) . Age is a major source of variability in all aspects of pharmacokinetics, including absorption, distribution, metabolism and elimination, and any of the above pharmacokinetic processes could potentially lead to inter-population (adults vs neonates) variation due to developmental changes (Marshall et al., 1998) . Despite these potentially large pharmacokinetic differences, legislation requiring paediatric clinical drug trials to be conducted is relatively new (Leong et al., 2012) .
The extensive practice of off-label prescribing in the paediatric population not only leads to a higher risk of adverse drug reactions, but also to low levels of efficacy due to suboptimal dosing of the therapeutic agent (Leong et al., 2012) . One of the reasons for this is that maturation of pharmacokinetic processes, such as metabolism and elimination, are not linear with age or bodyweight, thus allometric scaling of adult drug doses to paediatric dosing regimens results in unpredictable and often inaccurate paediatric doses (Espie, Tytgat, Sargentini-Maier, Poggesi, & Watelet, 2009; Johnson, Rostami-Hodjegan, & Tucker, 2006) . Allometric scaling methods, including bodyweight, the three-quarters exponent of bodyweight and body surface area, have been shown to both overand under-predict suitable doses across the paediatric dose range, emphasizing that children are not just small adults (Bouzom & Walther, 2008; Johnson, 2008) . Conversely, the physiologically-based pharmacokinetic (PBPK) approach, which integrates both physicochemical properties of the drug and physiological properties in a physiologically relevant compartmental structure, has demonstrated usefulness in the prediction of drug pharmacokinetics and inter-individual variability (Nestorov, 2003; Rostami-Hodjegan, 2012; Sager, Yu, Ragueneau-Majlessi, & Isoherranen, 2015) . When applied to a paediatric population, the system properties are parameterised with agedependent physiological parameters, such as tissue volumes and enzyme ontogeny (Johnson & Rostami-Hodjegan, 2011 ).
PBPK models are reported to produce superior predictions of concentration-time profiles compared with classic compartmental models, but are burdened by many disadvantages also, such as the need for detailed physiological and drug data, which may not be readily available (Bouzom & Walther, 2008; Sager et al., 2015) . The PBPK model can be used to predict drug exposure in different tissues as it encompasses each organ as a separate compartment, including inaccessible compartments such as the brain (Sager et al., 2015) . In this study, a PBPK model is employed to predict the concentration-time 
| MATERIALS AND METHODS

| Model structure
The Simcyp simulator V14 (Simcyp Ltd, Sheffield, UK) was used to provide the general structure of the developed PBPK model. The 4-compartmental permeability-limited brain 4brain model which is incorporated into the human whole body PBPK model of the Simcyp Simulator and has been described previously (Gaohua, Neuhoff, Johnson, Rostami-Hodjegan, & Jamei, 2016) was used to predict drug concentrations in the central nervous system (CNS) for this study.
Simcyp® is a population-based simulator that performs 'bottom-up' mechanistic modelling and simulation of absorption, distribution, metabolism and excretion processes to predict pharmacokinetic profiles and parameters of drugs and their variation between virtual subjects (Jamei et al., 2009 ).
| Model development
The model of bumetanide was developed as described in Figure 1 . The human PBPK model was used to predict bumetanide concentrations in a virtual adult population of healthy volunteers divided into ten trials with ten participants in each trial. Pharmacokinetic parameters from the simulated trials were compared with actual published plasma data from healthy volunteer adults from a total of five different studies (Cook et al., 1988; Holazo et al., 1984; Lau et al., 1986; Marcantonio et al., 1982; Oberbauer et al., 1995) . The developed model was ultimately used to predict the pharmacokinetics of bumetanide using Simcyp's Paediatric PBPK model, which was checked for accuracy using plasma samples collected from two trials, one involving a heterogeneous population of nine children with edema (ranging from 3 months to 11.5 years, with one participant aged 25 years) and the NEMO clinical study with 14 critically ill neonates with seizures (Marshall et al., 1998; Pressler et al., 2015 ; US National Institutes of Health, 2015) . Simulated trial designs, including the age ranges, male/ female ratios and dosing schedules for each respective virtual trial were based on published clinical trials.
Relevant physicochemical properties of bumetanide such as molecular weight, lipophilicity, ionisation constants and fraction unbound in plasma were collated from publications and entered as model inputs (Table 1) . Total intravenous clearance of bumetanide was calculated as the mean of the intravenous clearance reported in three studies, weighted based on sample size (Marcantonio et al., 1982; Oberbauer et al., 1995; Pentikainen et al., 1985) . Tissue partition coefficients of bumetanide were calculated using the Rodgers and Rowland algorithm (Simcyp Kp prediction method 2) (Rodgers & Rowland, 2007) 
| Model verification
Simulated trials yielded predictions of both pharmacokinetic parameters and concentration-time profiles. Pharmacokinetic parameter predictions were compared against observed values expressed in the literature. Predictions of pharmacokinetic parameters within two-fold of the observed value were considered to be reasonable predictions, as this is a frequently used criterion for accuracy (Musther et al., 2015) . Predicted concentration-time profiles were reported as mean, 5th and 95th percentile confidence intervals. Visual predictive checks against the observed mean concentrations ± standard deviations were used to confirm the model accuracy.
3 | RESULTS
| Model simulations of plasma bumetanide in adult populations
In humans, the PBPK model of bumetanide was verified in healthy adult volunteers using intravenous data (Table 2, Figure 2 ). The simulated output demonstrated a two-compartment profile, consistent with published pharmacokinetic models (Jullien et al., 2016; Marcantonio et al., 1982; Popovic et al., 2013) . Simulations of intravenous bolus injections generated reasonable pharmacokinetic predictions of area under the concentration-time curve (AUC) (0.71-1.15), peak plasma concentration (C max ) (0.62-1) and time to reach peak plasma concentration (t max ) (0.5-1) as shown by the predicted/observed ratios (Table 2 ) and concentration-time profiles overlaid with observed data (Figure 2) . As intravenous clearance differed between studies, a weighted mean of clearance was calculated from these studies based on sample size (Marcantonio et al., 1982; Oberbauer et al., 1995; Pentikainen et al., 1985) . Renal clearance values were similar across all studies, so a mean value was chosen (Marcantonio et al., 1982; Oberbauer et al., 1995) . The predictions made using the Simcyp model were within two-fold of observed values in adults, which meets the criteria for reasonable pharmacokinetic predictions (Table 2) .
| Model simulations of plasma bumetanide in paediatric populations
A paediatric PBPK model for bumetanide was developed using a similar approach to the adult model, this time using the in-built paediatric population in Simcyp®. The pharmacokinetic parameters estimated by the paediatric intravenous model were compared with the observed values (Table 3, Figure 3 ). The predicted pharmacokinetic parameters from a single intravenous dose of bumetanide in a virtual paediatric population comprising ten trials with ten participants each reflected observed data from a heterogeneous oedematous paediatric population well with predicted/observed ratios for AUC, C max and t max calculated as 1, 1.39 and 1, respectively.
Bumetanide plasma levels in neonates were shared with us by the consortium of NEMO trial members, and were used to compare with predicted bumetanide profiles in a virtual neonatal population (Table 4 , Figure 4) (Jullien et al., 2016; Pressler et al., 2015) . Since the true ontogeny is unknown, both the fast ontogeny and slow ontogeny scenarios were explored. The slow ontogeny function within Simcyp® was used to scale clearance of bumetanide to the paediatric population. However, AUC, C max and t max predicted by the neonatal model fell outside of acceptable limits in certain instances, which could be due to a number of reasons. The observed AUC was taken as the range (1.9-17.7 mg/l.h) reported for AUC of the first bumetanide dose which represents a 9.3-fold difference between maximum and minimum observed AUC, reflecting the large inter-individual variability in this critically ill neonatal population (Jullien et al., 2016) . Moreover, there is wide variability between the predicted/observed ratios for C max (0.87-2.24) and t max (0.76-2.4), depending on the dose. This may be partially due to sampling times as observed t max and C max data were taken from the sampled data instead of extrapolation of the sampled point and therefore may not reflect the actual peak values. The estimation of t max is complicated by the administration of bumetanide as a slow intravenous infusion.
| Model simulations of brain bumetanide in paediatric populations
The Kp brain was first estimated using Rodgers and Rowland mechanistic method in Simcyp®, which predicts drug distribution from physicochemical properties and in vitro data: this gave a predicted Kp brain in the paediatric population of 0.058. While Kp brain could have been estimated from previous in vitro experiments in which apparent permeability of bumetanide was measured (Donovan et al., 2016) , in vitro models have been noted to be poor at predicting the in vivo distribution of drugs and a battery of in vitro models would be required for accuracy (Garberg et al., 2005) . If brain bumetanide concentrations in adults were available to verify predicted concentrations, a similar approach to that taken by Johnson et al., in which in vitro data were generated to determine apparent permeability and the efflux ratio of antipsychotics at the BBB, could be utilised to determine bumetanide permeability at the human BBB . It has been
proposed that animal data on Kp can be incorporated into a PBPK model to ensure accurate distribution if such information is available (Musther et al., 2015) . Kp brain values are available in the literature for bumetanide in rat (Kp 0.01 (Donovan et al., 2015) ), mouse (Kp 0.015 (Tollner et al., 2015) ) and rats with seizures (Kp 0.06-0.26, Donovan, O'Driscoll et al., unpublished (Brandt et al., 2010) ). An estimation of total bumetanide concentration in brain mass was achieved by using each of these reported plasma: brain values to predict total brain bumetanide concentrations ( Figure 5 , Table 5 ). Across the four doses administered to neonates, there was a 14-fold difference between the C max achieved when Kp brain was 0.01 compared with 0.26. The predicted C max in brain ranged from 0.0043 mg/l to 0.361 mg/l.
These C max concentrations represent predictions of total brain concentrations of bumetanide; however, by taking into account that bumetanide has been shown to be highly brain-tissue bound (77% bound) (Donovan et al., 2016) , the only predicted concentration which achieves pharmacologically relevant unbound concentrations (0.073 mg/l and 0.109 mg/l) is 0.361 mg/l.
| DISCUSSION
The main objective of this study was to investigate if an in silico PBPK model could be used to predict bumetanide concentrations accurately in plasma and brain tissue in neonates with seizures. PBPK modelling is a method for the prediction of temporal drug concentrations in various organs, including the CNS (Wyska, Swierczek, Pociecha, & Przejczowska-Pomierny, 2015) . Using PBPK, it is possible to gain a prospective mechanistic understanding of the pharmacokinetics of a drug in the paediatric population, which facilitates optimal paediatric clinical trial design (Bjorkman, 2005) . PBPK predictions in neonates are acknowledged to be difficult due to the rapidly evolving physiology in this age group, including the changes in volume of distribution, hepatic and kidney function, and remodelling of the vasculature, leading to large inter-individual variability, as demonstrated in the predictions reported here (Bjorkman, 2005) . Nonetheless, it may be possible to define a systemic dose of bumetanide that would be predicted to lead to pharmacologically relevant unbound concentrations in the brain using in silico PBPK models.
There are reports of the successful use of PBPK in the prediction of paediatric pharmacokinetics and plasma concentration-time profiles of oseltamivir (Parrott et al., 2011) , clobazam and stiripentol (Ogungbenro & Aarons, 2015) , valproic acid (Ogungbenro & Aarons, 2014) , voriconazole (Zane & Thakker, 2014) , quetiapine , theophylline and midazolam (Bjorkman, 2005) , cyclosporine (Gerard et al., 2010) , moxifloxacin (Edginton, 2011) , sotalol (Khalil & Läer, 2014) at 12-hourly intervals on seizure control and reported an adverse benefit/risk ratio, which is likely to be partially due to low concentrations of bumetanide reaching the brain (Pressler et al., 2015) .
It is imperative that concentrations of neuroactive drugs at the site of action can be predicted, as they may differ greatly from exposure in other compartments due to a variety of factors including tissue volume, biochemical composition, active transport processes and metabolic clearance (de Lange, Ravenstijn, Groenendaal, & van Steeg, 2005; Kielbasa & Stratford, 2012) . The accurate prediction of drug concentrations in the human CNS from preclinical in vitro and in vivo be noted that only one neonate received the highest dose of 0.3 mg/ kg, and was administered three of the four possible doses at 12-hourly intervals (Pressler et al., 2015) . While no rescue antiepileptic medicines were required in this participant indicating drug efficacy, adverse effects of dehydration and hearing loss, which are at least partially bumetanide-related, were reported (Pressler et al., 2015) .
Following assessment of this in silico model's predictions, we can cautiously postulate that the concentration of bumetanide reaching the CNS in the neonates enrolled in the NEMO trial was sub-therapeutic. Strategies which can increase unbound concentrations of bumetanide in the brain in a safe and effective manner, such as OAT3 efflux transporter inhibition or prodrug administration need further exploration (Donovan et al., 2015 (Donovan et al., , 2016 Erker et al., 2016; Tollner et al., 2014 Tollner et al., , 2015 However, close monitoring would be required in either of these scenarios to ensure any risk of toxicity is minimised as all of these simulations were carried out retrospectively and fitted to clinical data (Edginton et al., 2006) . In silico models are a useful preclinical tool for estimation of concentrations in paediatric and neonatal populations; however, the paucity of physiological and transporter data in critically ill neonates with seizures, along with a lack of adult data, means that currently, the PBPK model developed here is not sufficiently robust to be used to completely bridge the knowledge gap between in vitro and in vivo studies to first-in-neonate dosing of bumetanide. This research has clearly shown that in silico 
